There are few fields of medicine in which the individualisation of medicines is more
important than in the area of oncology. Under‐dosing can have significant ramifications due …

The treatment of psoriasis has been revolutionized by the emergence of biological
therapies. Monoclonal antibodies (mAb) generally have complex pharmacokinetic (PK) …

Amyotrophic Lateral Sclerosis (ALS) is a mid-life onset neurodegenerative disease that
manifests its symptomatology with motor impairments and cognitive deficits overlapping with …

Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA
approvals in the last two years and a projected market value of over $4 billion by 2024 …

Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM)
cells have Fc-dependent immune effector mechanisms, such as complement-dependent …

Monoclonal Antibodies (mAbs) are being used in the treatment of both malignant and non-
malignant diseases and whilst highly effective, certain products have very short expiry times …

The timely distribution of medicines to patients is an essential part of the patient care plan,
and maximising efficiency in the logistics systems behind these movements is vital to …

Therapeutic drug monitoring (TDM) is typically referred to as the measurement of the
concentration of drugs in patient blood. Although in the past, TDM was restricted to drugs …

The use of monoclonal antibody (mAb) therapeutics is increasing rapidly, but mAb
concentrations vary widely between individuals and might subsequently affect mAb …

Control of monoclonal antibody (mAb) concentrations in serum is important for maintaining
the safety and efficacy of these lifesaving therapeutics. Point-of-care (POC) quantification of …